Day One Biopharmaceuticals (NASDAQ:DAWN) PT Lowered to $40.00 at HC Wainwright

Day One Biopharmaceuticals (NASDAQ:DAWN) had its target price cut by analysts at HC Wainwright from $50.00 to $40.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 143.75% from the company’s current price.

Several other research analysts have also recently weighed in on DAWN. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Piper Sandler reissued an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. The Goldman Sachs Group lowered their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Needham & Company LLC boosted their price target on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Finally, Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, April 24th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Day One Biopharmaceuticals Stock Performance

NASDAQ:DAWN opened at $16.41 on Tuesday. The stock has a 50 day moving average price of $15.46 and a 200 day moving average price of $14.17. The stock has a market cap of $1.43 billion, a PE ratio of -6.89 and a beta of -1.44. Day One Biopharmaceuticals has a one year low of $9.67 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, analysts predict that Day One Biopharmaceuticals will post -2.67 earnings per share for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the sale, the insider now directly owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the sale, the insider now directly owns 1,244,662 shares in the company, valued at $18,981,095.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Charles N. York II sold 2,666 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the sale, the chief financial officer now owns 277,754 shares in the company, valued at $4,235,748.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 195,247 shares of company stock worth $3,376,817. Company insiders own 8.40% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

A number of large investors have recently made changes to their positions in the company. Summit Rock Advisors LP acquired a new position in Day One Biopharmaceuticals in the first quarter valued at approximately $851,000. ProShare Advisors LLC boosted its holdings in Day One Biopharmaceuticals by 9.1% in the first quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after purchasing an additional 1,447 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Day One Biopharmaceuticals by 67.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 16,817 shares of the company’s stock valued at $278,000 after purchasing an additional 6,750 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in Day One Biopharmaceuticals by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after purchasing an additional 1,445 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in Day One Biopharmaceuticals by 89.0% in the fourth quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock valued at $999,000 after purchasing an additional 32,238 shares in the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.